Cardiff Oncology Inc (CRDF)

$0.89 -0.02 (-2.01%)
Market Cap 70.35M
Revenue (ttm) 590,000.00
Net Income (ttm) -45.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,771.19%
Debt to Equity Ratio 0.00
Volume 597,100
Avg Vol 1,384,374
Day's Range N/A - N/A
Shares Out 77.80M
Stochastic %K 7%
Beta 1.50
Analysts Sell
Price Target $5.45

Company Profile

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative brea...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 952 7570
Address:
11055 Flintkote Avenue, San Diego, United States
Teskonik
Teskonik Aug. 19 at 3:00 PM
$CRDF what a judge don't like is picking raisins. if nms do so, ...needs DD.
0 · Reply
Csab6362
Csab6362 Aug. 19 at 2:05 PM
$CRDF Will we see PI decision before meeting? 🤔 It definitely could help to bring this to an end
4 · Reply
Blakeruss1
Blakeruss1 Aug. 19 at 1:34 PM
$CRDF crazy volume
0 · Reply
spotit
spotit Aug. 19 at 1:00 PM
$CRDF and this is phase 3 Cancer treatment ? $1000+ 😊 $MRNA
0 · Reply
Timtim113
Timtim113 Aug. 19 at 12:55 PM
$CRDF Everyone absolutely loathes PAG. It doesn't take deep analysis to see that this isn't about NMS—it’s simply about their agenda. Right now, the only things I believe in are Kourtney Mueller Merrill’s track record and strategy. Everything hinges on her. I trust that her creative success in the early stages will pay off this time, too. Let’s wait and see. If we win this match, the Cardiff clinical data makes us champions. But if we can't even get into the game—or if our license gets revoked—we’ll never be able to prove it. I love you all. Seriously—though only the "Longs" among you.
2 · Reply
Blakeruss1
Blakeruss1 Aug. 19 at 12:25 PM
$CRDF solid pre. Expect PI today
0 · Reply
jrh34
jrh34 Aug. 19 at 11:10 AM
$CRDF weak legal standing so NMS pays individuals to post FUD. Lots of Chinese money involved. Company won’t ever get to reverse split. It’s A legal win and sell to $PFE or it’s CH11 those are the only two options.
0 · Reply
Lord_Andrew_London
Lord_Andrew_London Aug. 19 at 11:06 AM
$CRDF Things are going as I said for Nerviano. They tried to sell themselves for a long time since were facing closure. The Chinese know that Is not a Company,Is a research laboratory with half of the people already gone. It does not look like a big deal to me.
0 · Reply
Huber65
Huber65 Aug. 19 at 11:03 AM
$CRDF my feeling is the delay in conference is positive for Crdf . Nerviano must be at a crossroad. Why they need weekend for decision seems like a desperate move . Could be 100 percent wrong
1 · Reply
Teskonik
Teskonik Aug. 19 at 10:03 AM
$CRDF nms is for sale now. take your advantage.
1 · Reply
Latest News on CRDF
Cardiff Oncology reports Q2 EPS (14c), consensus (16c)

2026-08-17T11:11:04.000Z - 2 days ago

Cardiff Oncology reports Q2 EPS (14c), consensus (16c)

Cardiff Oncology downgraded to Market Perform from Outperform at William Blair

2026-08-17T11:06:12.000Z - 2 days ago

Cardiff Oncology downgraded to Market Perform from Outperform at William Blair

Cardiff Oncology Proxy statement: Proxy filing

Aug 14, 2026, 8:00 AM EDT - 5 days ago

Cardiff Oncology Proxy statement: Proxy filing

Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update

Aug 11, 2026, 4:10 PM EDT - 7 days ago

Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update

Cardiff Oncology Quarterly report: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 8 days ago

Cardiff Oncology Quarterly report: Q2 2026

Cardiff Oncology Earnings release: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 8 days ago

Cardiff Oncology Earnings release: Q2 2026

Cardiff Oncology announces $10M registered direct offering

2026-07-15T12:15:16.000Z - 5 weeks ago

Cardiff Oncology announces $10M registered direct offering

Cardiff Oncology Announces $10 Million Registered Direct Offering

Jul 15, 2026, 8:00 AM EDT - 5 weeks ago

Cardiff Oncology Announces $10 Million Registered Direct Offering

Cardiff Oncology price target lowered to $4 from $10 at Lucid Capital

2026-06-05T11:13:07.000Z - 2 months ago

Cardiff Oncology price target lowered to $4 from $10 at Lucid Capital

Cardiff Oncology Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 10:30 AM EDT - 2 months ago

Cardiff Oncology Transcript: Jefferies Global Healthcare Conference 2026

Craig-Hallum downgrades Cardiff Oncology to Hold, lowers target to $2

2026-06-03T16:55:09.000Z - 2 months ago

Craig-Hallum downgrades Cardiff Oncology to Hold, lowers target to $2

Cardiff Oncology downgraded to Hold from Buy at Craig-Hallum

2026-06-03T16:07:35.000Z - 2 months ago

Cardiff Oncology downgraded to Hold from Buy at Craig-Hallum

Cardiff Oncology Transcript: Status update

Jun 3, 2026, 8:30 AM EDT - 2 months ago

Cardiff Oncology Transcript: Status update

Cardiff Oncology Press release: Status update

Jun 3, 2026, 8:30 AM EDT - 2 months ago

Cardiff Oncology Press release: Status update

Cardiff Oncology Slides: Status update

Jun 3, 2026, 8:30 AM EDT - 2 months ago

Cardiff Oncology Slides: Status update

Cardiff Oncology announces results from CRDF-004 trial

2026-06-02T14:11:15.000Z - 2 months ago

Cardiff Oncology announces results from CRDF-004 trial

Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting

Jun 2, 2026, 9:06 AM EDT - 2 months ago

Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting

Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference

Jun 1, 2026, 4:01 PM EDT - 2 months ago

Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference

Cardiff Oncology downgraded to Neutral from Buy at H.C. Wainwright

2026-06-01T10:28:20.000Z - 2 months ago

Cardiff Oncology downgraded to Neutral from Buy at H.C. Wainwright

Cardiff Oncology says NMS terminating license agreement

2026-06-01T10:26:56.000Z - 2 months ago

Cardiff Oncology says NMS terminating license agreement

Cardiff Oncology downgraded to Hold from Buy at TD Cowen

2026-06-01T10:26:21.000Z - 2 months ago

Cardiff Oncology downgraded to Hold from Buy at TD Cowen

Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC

May 21, 2026, 5:00 PM EDT - 3 months ago

Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC

Cardiff Oncology reports Q1 EPS (18c), consensus (12c)

2026-05-14T21:00:37.000Z - 3 months ago

Cardiff Oncology reports Q1 EPS (18c), consensus (12c)

Cardiff Oncology sees cash, equivalents funding operations into 1Q27

2026-05-14T20:59:48.000Z - 3 months ago

Cardiff Oncology sees cash, equivalents funding operations into 1Q27

Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update

May 14, 2026, 4:10 PM EDT - 3 months ago

Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update

Cardiff Oncology Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 3 months ago

Cardiff Oncology Quarterly report: Q1 2026

Cardiff Oncology Earnings release: Q1 2026

May 14, 2026, 7:00 AM EDT - 3 months ago

Cardiff Oncology Earnings release: Q1 2026

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 28, 2026, 4:01 PM EDT - 4 months ago

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib's Promising Single-Agent Activity

Apr 27, 2026, 7:00 AM EDT - 4 months ago

Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib's Promising Single-Agent Activity

Cardiff Oncology Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Cardiff Oncology Proxy statement: Proxy filing

Cardiff Oncology Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Cardiff Oncology Proxy statement: Proxy filing

Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026

Apr 21, 2026, 10:00 AM EDT - 4 months ago

Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026

Cardiff Oncology to present preclinical data on onvansertib

2026-04-17T20:14:54.000Z - 4 months ago

Cardiff Oncology to present preclinical data on onvansertib

Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting

Apr 17, 2026, 4:01 PM EDT - 4 months ago

Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting

Cardiff Oncology appoints Mani Mohindru CEO, Josh Muntner CFO

2026-04-09T20:11:39.000Z - 4 months ago

Cardiff Oncology appoints Mani Mohindru CEO, Josh Muntner CFO

ACRS

Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth

Apr 9, 2026, 4:01 PM EDT - 4 months ago

Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth

Cardiff Oncology Transcript: KOL event

Mar 25, 2026, 4:30 PM EDT - 5 months ago

Cardiff Oncology Transcript: KOL event

Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer

Mar 20, 2026, 7:00 AM EDT - 5 months ago

Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer

Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting

Mar 19, 2026, 7:00 AM EDT - 5 months ago

Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

Feb 26, 2026, 4:01 PM EST - 6 months ago

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

Cardiff Oncology Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 25, 2026, 1:20 PM EST - 6 months ago

Cardiff Oncology Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Cardiff Oncology price target lowered to $6 from $10 at Piper Sandler

2026-02-25T12:21:13.000Z - 6 months ago

Cardiff Oncology price target lowered to $6 from $10 at Piper Sandler

Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update

Feb 24, 2026, 4:30 PM EST - 6 months ago

Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update

Cardiff Oncology Earnings release: Q4 2025

Feb 24, 2026, 7:00 AM EST - 6 months ago

Cardiff Oncology Earnings release: Q4 2025

Cardiff Oncology Annual report: Q4 2025

Feb 24, 2026, 7:00 AM EST - 6 months ago

Cardiff Oncology Annual report: Q4 2025

Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 19, 2026, 7:00 AM EST - 6 months ago

Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Cardiff Oncology selloff brings attractive entry point, says H.C. Wainwright

2026-01-28T11:15:48.000Z - 7 months ago

Cardiff Oncology selloff brings attractive entry point, says H.C. Wainwright

Cardiff Oncology Transcript: Study result

Jan 27, 2026, 8:30 AM EST - 7 months ago

Cardiff Oncology Transcript: Study result

Cardiff Oncology Press release: Study result

Jan 27, 2026, 8:30 AM EST - 7 months ago

Cardiff Oncology Press release: Study result

Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

Jan 27, 2026, 7:05 AM EST - 7 months ago

Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

Jan 27, 2026, 7:00 AM EST - 7 months ago

Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

CTMX

Cardiff Oncology Slides: Company presentation

Jan 7, 2026, 7:00 AM EST - 8 months ago

Cardiff Oncology Slides: Company presentation

Cardiff Oncology Transcript: Sidoti's Year End Virtual Investor Conference

Dec 11, 2025, 4:00 PM EST - 8 months ago

Cardiff Oncology Transcript: Sidoti's Year End Virtual Investor Conference

Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025

Dec 8, 2025, 4:05 PM EST - 9 months ago

Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025

Cardiff Oncology to Present at Sidoti's Year-End Virtual Investor Conference

Dec 8, 2025, 7:00 AM EST - 9 months ago

Cardiff Oncology to Present at Sidoti's Year-End Virtual Investor Conference

Cardiff Oncology Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 9:30 AM EST - 9 months ago

Cardiff Oncology Transcript: Piper Sandler 37th Annual Healthcare Conference

Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 7:00 AM EST - 9 months ago

Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference

Cardiff Oncology Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 9:20 AM EST - 10 months ago

Cardiff Oncology Transcript: Stifel 2025 Healthcare Conference

Cardiff Oncology Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 9:30 AM EST - 10 months ago

Cardiff Oncology Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update

Nov 6, 2025, 4:05 PM EST - 10 months ago

Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update

Cardiff Oncology Earnings release: Q3 2025

Nov 6, 2025, 4:00 PM EST - 10 months ago

Cardiff Oncology Earnings release: Q3 2025

Cardiff Oncology Quarterly report: Q3 2025

Nov 6, 2025, 4:00 PM EST - 10 months ago

Cardiff Oncology Quarterly report: Q3 2025

Cardiff Oncology to Participate in Two Upcoming Investor Conferences

Nov 4, 2025, 4:01 PM EST - 10 months ago

Cardiff Oncology to Participate in Two Upcoming Investor Conferences

Cardiff Oncology Transcript: Noble Capital Markets Emerging Growth Virtual Investor Conference

Oct 9, 2025, 2:00 PM EDT - 11 months ago

Cardiff Oncology Transcript: Noble Capital Markets Emerging Growth Virtual Investor Conference

Cardiff Oncology Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 10:30 AM EDT - 1 year ago

Cardiff Oncology Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

Aug 28, 2025, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

Cardiff Oncology Transcript: Study Update

Jul 29, 2025, 4:30 PM EDT - 1 year ago

Cardiff Oncology Transcript: Study Update

Cardiff Oncology Press release: Study Update

Jul 29, 2025, 4:30 PM EDT - 1 year ago

Cardiff Oncology Press release: Study Update

Cardiff Oncology Slides: Study Update

Jul 29, 2025, 4:30 PM EDT - 1 year ago

Cardiff Oncology Slides: Study Update

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

Jul 29, 2025, 4:07 PM EDT - 1 year ago

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

Cardiff Oncology Earnings release: Q2 2025

Jul 29, 2025, 7:00 AM EDT - 1 year ago

Cardiff Oncology Earnings release: Q2 2025

Cardiff Oncology Quarterly report: Q2 2025

Jul 29, 2025, 7:00 AM EDT - 1 year ago

Cardiff Oncology Quarterly report: Q2 2025

Cardiff Oncology Names Roger Sidhu as Medical Chief

Jun 17, 2025, 4:39 PM EDT - 1 year ago

Cardiff Oncology Names Roger Sidhu as Medical Chief

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

Jun 17, 2025, 4:05 PM EDT - 1 year ago

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

Jun 2, 2025, 4:05 PM EDT - 1 year ago

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

May 8, 2025, 4:05 PM EDT - 1 year ago

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

Cardiff Oncology Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Cardiff Oncology Earnings release: Q1 2025

Cardiff Oncology Quarterly report: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Cardiff Oncology Quarterly report: Q1 2025

Cardiff Oncology Registration statement: Registration Filing

May 8, 2025, 8:00 AM EDT - 1 year ago

Cardiff Oncology Registration statement: Registration Filing

Cardiff Oncology Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Cardiff Oncology Proxy statement: Proxy Filing

Cardiff Oncology Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Cardiff Oncology Proxy statement: Proxy Filing

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Apr 15, 2025, 4:05 PM EDT - 1 year ago

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Cardiff Oncology Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 5, 2025, 11:50 AM EST - 1 year ago

Cardiff Oncology Transcript: TD Cowen 45th Annual Healthcare Conference

Cardiff Oncology Earnings Call Transcript: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Cardiff Oncology Earnings Call Transcript: Q4 2024

Cardiff Oncology Earnings release: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Cardiff Oncology Earnings release: Q4 2024

Cardiff Oncology Annual report: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Cardiff Oncology Annual report: Q4 2024

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Feb 27, 2025, 4:05 PM EST - 1 year ago

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Cardiff Oncology Registration statement: Registration Filing

Feb 27, 2025, 7:00 AM EST - 1 year ago

Cardiff Oncology Registration statement: Registration Filing

Cardiff Oncology to Present at Upcoming Investor Conferences

Feb 24, 2025, 4:05 PM EST - 1 year ago

Cardiff Oncology to Present at Upcoming Investor Conferences

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Feb 20, 2025, 4:05 PM EST - 1 year ago

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Cardiff Oncology Transcript: Study Result

Dec 10, 2024, 8:00 AM EST - 1 year ago

Cardiff Oncology Transcript: Study Result

Cardiff Oncology Press release: Study Result

Dec 10, 2024, 8:00 AM EST - 1 year ago

Cardiff Oncology Press release: Study Result

Cardiff Oncology Slides: Study Result

Dec 10, 2024, 8:00 AM EST - 1 year ago

Cardiff Oncology Slides: Study Result

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Dec 10, 2024, 7:20 AM EST - 1 year ago

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

Dec 10, 2024, 6:00 AM EST - 1 year ago

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

Cardiff Oncology Quarterly report: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Cardiff Oncology Quarterly report: Q3 2024

Cardiff Oncology Earnings release: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Cardiff Oncology Earnings release: Q3 2024

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

Cardiff Oncology Earnings Call Transcript: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Cardiff Oncology Earnings Call Transcript: Q2 2024

Cardiff Oncology Quarterly report: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Cardiff Oncology Quarterly report: Q2 2024

Cardiff Oncology Earnings release: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Cardiff Oncology Earnings release: Q2 2024

Cardiff Oncology Proxy statement: Proxy Filing

Jun 17, 2024, 8:00 AM EDT - 2 years ago

Cardiff Oncology Proxy statement: Proxy Filing

Cardiff Oncology Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 8:30 AM EDT - 2 years ago

Cardiff Oncology Transcript: Jefferies 2024 Global Healthcare Conference

Cardiff Oncology Proxy statement: Proxy Filing

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Cardiff Oncology Proxy statement: Proxy Filing

Cardiff Oncology to Present at the Jefferies Healthcare Conference

May 29, 2024, 4:05 PM EDT - 2 years ago

Cardiff Oncology to Present at the Jefferies Healthcare Conference

Cardiff Oncology Transcript: TD Cowen 5th Annual Oncology Innovation Virtual Summit

May 29, 2024, 1:30 PM EDT - 2 years ago

Cardiff Oncology Transcript: TD Cowen 5th Annual Oncology Innovation Virtual Summit

Cardiff Oncology Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 20, 2024, 2:30 PM EDT - 2 years ago

Cardiff Oncology Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Cardiff Oncology to Present at Upcoming Investor Conferences in May

May 13, 2024, 4:05 PM EDT - 2 years ago

Cardiff Oncology to Present at Upcoming Investor Conferences in May

Cardiff Oncology Earnings Call Transcript: Q1 2024

May 2, 2024, 4:30 PM EDT - 2 years ago

Cardiff Oncology Earnings Call Transcript: Q1 2024

Cardiff Oncology Quarterly report: Q1 2024

May 2, 2024, 4:30 PM EDT - 2 years ago

Cardiff Oncology Quarterly report: Q1 2024

Cardiff Oncology Earnings release: Q1 2024

May 2, 2024, 4:30 PM EDT - 2 years ago

Cardiff Oncology Earnings release: Q1 2024

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

May 2, 2024, 4:05 PM EDT - 2 years ago

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

Apr 25, 2024, 4:05 PM EDT - 2 years ago

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

Cardiff Oncology Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Cardiff Oncology Proxy statement: Proxy Filing

Cardiff Oncology Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Cardiff Oncology Proxy statement: Proxy Filing

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

Apr 8, 2024, 4:05 PM EDT - 2 years ago

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

Mar 6, 2024, 4:05 PM EST - 2 years ago

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

Cardiff Oncology Transcript: TD Cowen 44th Annual Health Care Conference 2024

Mar 4, 2024, 1:30 PM EST - 2 years ago

Cardiff Oncology Transcript: TD Cowen 44th Annual Health Care Conference 2024

Cardiff Oncology Earnings Call Transcript: Q4 2023

Feb 29, 2024, 4:30 PM EST - 2 years ago

Cardiff Oncology Earnings Call Transcript: Q4 2023

Cardiff Oncology Earnings release: Q4 2023

Feb 29, 2024, 4:30 PM EST - 2 years ago

Cardiff Oncology Earnings release: Q4 2023

Cardiff Oncology Annual report: Q4 2023

Feb 29, 2024, 4:30 PM EST - 2 years ago

Cardiff Oncology Annual report: Q4 2023

Cardiff Oncology Slides: Q4 2023

Feb 29, 2024, 4:30 PM EST - 2 years ago

Cardiff Oncology Slides: Q4 2023

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Feb 29, 2024, 4:07 PM EST - 2 years ago

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC

Feb 29, 2024, 4:06 PM EST - 2 years ago

Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

Feb 29, 2024, 4:05 PM EST - 2 years ago

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference

Feb 26, 2024, 8:00 AM EST - 2 years ago

Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference

Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update

Feb 22, 2024, 8:00 AM EST - 2 years ago

Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update

Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research

Jan 17, 2024, 10:30 AM EST - 2 years ago

Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research

Cardiff Oncology Transcript: Piper Sandler 35th Annual Healthcare Conference

Nov 29, 2023, 10:00 AM EST - 2 years ago

Cardiff Oncology Transcript: Piper Sandler 35th Annual Healthcare Conference

Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 20, 2023, 4:05 PM EST - 2 years ago

Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference

Teskonik
Teskonik Aug. 19 at 3:00 PM
$CRDF what a judge don't like is picking raisins. if nms do so, ...needs DD.
0 · Reply
Csab6362
Csab6362 Aug. 19 at 2:05 PM
$CRDF Will we see PI decision before meeting? 🤔 It definitely could help to bring this to an end
4 · Reply
Blakeruss1
Blakeruss1 Aug. 19 at 1:34 PM
$CRDF crazy volume
0 · Reply
spotit
spotit Aug. 19 at 1:00 PM
$CRDF and this is phase 3 Cancer treatment ? $1000+ 😊 $MRNA
0 · Reply
Timtim113
Timtim113 Aug. 19 at 12:55 PM
$CRDF Everyone absolutely loathes PAG. It doesn't take deep analysis to see that this isn't about NMS—it’s simply about their agenda. Right now, the only things I believe in are Kourtney Mueller Merrill’s track record and strategy. Everything hinges on her. I trust that her creative success in the early stages will pay off this time, too. Let’s wait and see. If we win this match, the Cardiff clinical data makes us champions. But if we can't even get into the game—or if our license gets revoked—we’ll never be able to prove it. I love you all. Seriously—though only the "Longs" among you.
2 · Reply
Blakeruss1
Blakeruss1 Aug. 19 at 12:25 PM
$CRDF solid pre. Expect PI today
0 · Reply
jrh34
jrh34 Aug. 19 at 11:10 AM
$CRDF weak legal standing so NMS pays individuals to post FUD. Lots of Chinese money involved. Company won’t ever get to reverse split. It’s A legal win and sell to $PFE or it’s CH11 those are the only two options.
0 · Reply
Lord_Andrew_London
Lord_Andrew_London Aug. 19 at 11:06 AM
$CRDF Things are going as I said for Nerviano. They tried to sell themselves for a long time since were facing closure. The Chinese know that Is not a Company,Is a research laboratory with half of the people already gone. It does not look like a big deal to me.
0 · Reply
Huber65
Huber65 Aug. 19 at 11:03 AM
$CRDF my feeling is the delay in conference is positive for Crdf . Nerviano must be at a crossroad. Why they need weekend for decision seems like a desperate move . Could be 100 percent wrong
1 · Reply
Teskonik
Teskonik Aug. 19 at 10:03 AM
$CRDF nms is for sale now. take your advantage.
1 · Reply
PeterTheFrog
PeterTheFrog Aug. 19 at 8:50 AM
$CRDF I am still with you my fellow smart CRDF bulls! I am not selling a single CRDF share only buying :)
0 · Reply
spaarrow1
spaarrow1 Aug. 19 at 8:10 AM
$CRDF what is this stupid talk about RS? What are u guys doing? U sell AT 0.9 because u guys are affraid of RS? Seriously...
0 · Reply
BioGypsy
BioGypsy Aug. 19 at 8:00 AM
$CRDF the Jl or yahoo account resurfaced again in yahoo blabbering more AI as a disguised legal expert. People need to go see all his comments. He is a blabbering dolt. The give way again is his intent to build a case for a RS. There is absolutely zero reason for Crdf to entertain a RS at this point. 5 months from now if we are still sub 1$ and facing more delays, yes. But any rambling of that now has motive to scare retail. He is a very evil and dishonest person. Far worse than any pumper
0 · Reply
Huber65
Huber65 Aug. 19 at 7:58 AM
$CRDF conference reset
1 · Reply
BioGypsy
BioGypsy Aug. 19 at 7:41 AM
$CRDF interesting shift to Monday!
1 · Reply
spaarrow1
spaarrow1 Aug. 19 at 7:14 AM
$CRDF Any1 Who sell AT this price is a moron.
0 · Reply
spaarrow1
spaarrow1 Aug. 19 at 7:07 AM
$CRDF I sometime Wonder in my heart. If some of these bears Who yello for chapter 11 etc. Arent the guy personalky sittning at GS office in NY shorting the stock. Wallstreet always wins cause, retail sells when stock is all time low. Have u guys never wondered how Tesla Could 2012 fall to 0.95? Ppl sold out of fear.
0 · Reply
biohuntress
biohuntress Aug. 19 at 5:50 AM
$CRDF Frontage Inc which is headquartered in Shanghai acquired NMS Accelera CRO... PAG, SARI, Frontage are all Chinese....it looks like the whole NMS operation now in Chinese hands.....they have a footprint in the US...." The Chinese investor aims to bring the innovative drugs discovered in Nerviano to the large Chinese patient population to improve their quality of life.".......bullseye on Onva I presume
1 · Reply
Quinn1614
Quinn1614 Aug. 19 at 3:29 AM
$CRDF new posting. Is it anything. Minute Order by Magistrate Judge Jill L. Burkhardt: At the request of Defendant, and with Plaintiff's agreement, the Status Conference set for 08/21/2026, is hereby RESET to 8/24/2026, at 10:00 AM before Magistrate Judge Jill L. Burkhardt. For purposes of the conference, all participating counsel shall call the Court's teleconference line at 691-657-0657 and use conference id number 165 498 779#. (nxo.) (Entered on 08/18/2026.)
0 · Reply
jakeguess
jakeguess Aug. 19 at 3:22 AM
$CRDF what drives me crazy is Mani online linkedin and liking posts but cant give us stakeholders anything. Give us something settle with Nms.
0 · Reply
Cossandon
Cossandon Aug. 19 at 2:54 AM
$CRDF Regarding the NMS facility closing auction, I took a look at the source code (html) of the auction website. The timestamps on the photos are interesting, because the source code for EquipNet’s NMS facility-closure auction includes image filenames that have timestamps of November and December of 2025 for the items for listed for bid. That period appears to overlap with the early phases of the NMS–Cardiff disputes, but before NMS issued its formal February 18, 2026 breach notice. Doesn't prove anything. But interesting tidbit of information. I was wondering when the auction was first posted online, couldn't find that in the source code, but the timestamps on the photos are there as public info, if you know where to look. https://www.equipnet.com/auctions/nerviano/1609
1 · Reply
Javiergame4
Javiergame4 Aug. 19 at 1:15 AM
$CRDF are we screwed with crdf guys ? are you still bullish?
3 · Reply